Medtronic Execs Pin Growth Plans On Diabetes, Robotic Surgery

After reporting a $1 million loss for the same period one year earlier, Medtronic defied analysts’ expectations to bounce back and earn $1.1 billion in the fourth quarter ended April 29, boosted by the acquisition of Covidien. Strong demand for cardiovascular and diabetes device sales paced all product segments during the period.